UK MHRA Approves Retifanlimab for Merkel Cell Skin Cancer
The UK MHRA has approved retifanlimab (ZYNYZ) for the treatment of advanced Merkel Cell Carcinoma (MCC), a rare and aggressive skin cancer with significant unmet medical need.
UK Drug Approval | 08/07/2026 | By Akanki
UK MHRA Approves Vyjuvek for Treatment of Dystrophic Epidermolysis Bullosa Wounds
Medicines and Healthcare products Regulatory Agency has approved Vyjuvek for treating wounds in patients with dystrophic epidermolysis bullosa, including newborns.
UK Drug Approval | 18/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy